Alx Oncology
NASDAQ: ALXOIncorporated in Delaware · 4 known investors
ALX Oncology is a clinical-stage biopharmaceutical company developing cancer therapies, including its lead candidate evorpacept for immuno-oncology and ALX2004, an antibody-drug conjugate targeting EGFR-positive tumors. Its work focuses on novel treatments intended to extend the lives of cancer patients.
BiotechHealthtech
Investors · 4
Competitors · 2
by search overlapExelixis21 shared keywordsExelixis is a biopharmaceutical company developing cancer therapies through biotherapeutics and small molecule programs, including bispecific antibodies and antibody-drug conjugates. It advances anti-cancer treatments internally and via industry collaborations across multiple modalities in biologics and small molecules.
Solu16 shared keywordsSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
Companies competing with Alx Oncology for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Alx Oncology do?
- ALX Oncology is a clinical-stage biopharmaceutical company developing cancer therapies, including its lead candidate evorpacept for immuno-oncology and ALX2004, an antibody-drug conjugate targeting EGFR-positive tumors. Its work focuses on novel treatments intended to extend the lives of cancer patients.
- Who are Alx Oncology's investors?
- Alx Oncology's investors include age1, Foresite Capital, Lightstone Ventures, venBio Partners.